These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 9796965)

  • 1. Augmented capillary leak during isolated hepatic perfusion (IHP) occurs via tumor necrosis factor-independent mechanisms.
    Alexander HR; Brown CK; Bartlett DL; Libutti SK; Figg WD; Raje S; Turner E
    Clin Cancer Res; 1998 Oct; 4(10):2357-62. PubMed ID: 9796965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver.
    Alexander HR; Libutti SK; Bartlett DL; Puhlmann M; Fraker DL; Bachenheimer LC
    Clin Cancer Res; 2000 Aug; 6(8):3062-70. PubMed ID: 10955785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic vascular isolation and perfusion for patients with progressive unresectable liver metastases from colorectal carcinoma refractory to previous systemic and regional chemotherapy.
    Alexander HR; Libutti SK; Bartlett DL; Pingpank JF; Kranda K; Helsabeck C; Beresnev T
    Cancer; 2002 Aug; 95(4):730-6. PubMed ID: 12209715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of tumor necrosis factor on toxicity and cytokine production after isolated hepatic perfusion.
    Lans TE; Bartlett DL; Libutti SK; Gnant MF; Liewehr DJ; Venzon DJ; Turner EM; Alexander HR
    Clin Cancer Res; 2001 Apr; 7(4):784-90. PubMed ID: 11309322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isolated hepatic perfusion with high-dose melphalan results in immediate alterations in tumor gene expression in patients with metastatic ocular melanoma.
    Varghese S; Xu H; Bartlett D; Hughes M; Pingpank JF; Beresnev T; Alexander HR
    Ann Surg Oncol; 2010 Jul; 17(7):1870-7. PubMed ID: 20221901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic antitumor effects of histamine plus melphalan in isolated hepatic perfusion for liver metastases.
    Brunstein F; Eggermont AM; de Wiel-Ambagtsheer Ga; van Tiel ST; Rens J; ten Hagen TL
    Ann Surg Oncol; 2007 Feb; 14(2):795-801. PubMed ID: 17096052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isolated hepatic perfusion for the treatment of colorectal metastases confined to the liver: recent trends and perspectives.
    Rothbarth J; Tollenaar RA; Schellens JH; Nortier JW; Kool LJ; Kuppen PJ; Mulder GJ; van de Velde CJ
    Eur J Cancer; 2004 Aug; 40(12):1812-24. PubMed ID: 15288282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer.
    Bartlett DL; Libutti SK; Figg WD; Fraker DL; Alexander HR
    Surgery; 2001 Feb; 129(2):176-87. PubMed ID: 11174711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of hyperthermic isolated limb perfusion with recombinant tumor necrosis factor alpha and melphalan on the human fibrinolytic system.
    Zwaveling JH; Maring JK; Mulder AB; Bom VJ; van Ginkel RJ; Schraffordt Koops H; Girbes AR; Hoekstra HJ; van der Meer J
    Cancer Res; 1996 Sep; 56(17):3948-53. PubMed ID: 8752162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complete response of melanoma-in-transit metastasis after isolated limb perfusion with tumor necrosis factor alpha and melphalan without massive tumor necrosis: a clinical and histopathological study of the delayed-type reaction pattern.
    Nooijen PT; Eggermont AM; Schalkwijk L; Henzen-Logmans S; de Waal RM; Ruiter DJ
    Cancer Res; 1998 Nov; 58(21):4880-7. PubMed ID: 9809994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
    Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB
    Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver.
    Alexander HR; Bartlett DL; Libutti SK; Fraker DL; Moser T; Rosenberg SA
    J Clin Oncol; 1998 Apr; 16(4):1479-89. PubMed ID: 9552055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic antitumor activity of histamine plus melphalan in isolated limb perfusion: preclinical studies.
    Brunstein F; Hoving S; Seynhaeve AL; van Tiel ST; Guetens G; de Bruijn EA; Eggermont AM; ten Hagen TL
    J Natl Cancer Inst; 2004 Nov; 96(21):1603-10. PubMed ID: 15523089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of isolated hepatic perfusion with high dose tumor necrosis factor in rat model.
    Nakamoto T; Inagawa H; Takagi K; Tashiro K; Yoshimura H; Nishizawa T; Honda T; Kanou J; Muto Y; Amm E; Soma G
    Anticancer Res; 2000; 20(1C):619-22. PubMed ID: 10769705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020.
    Cornett WR; McCall LM; Petersen RP; Ross MI; Briele HA; Noyes RD; Sussman JJ; Kraybill WG; Kane JM; Alexander HR; Lee JE; Mansfield PF; Pingpank JF; Winchester DJ; White RL; Chadaram V; Herndon JE; Fraker DL; Tyler DS;
    J Clin Oncol; 2006 Sep; 24(25):4196-201. PubMed ID: 16943537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early destruction of tumor vasculature in tumor necrosis factor-alpha-based isolated limb perfusion is responsible for tumor response.
    Hoving S; Seynhaeve AL; van Tiel ST; aan de Wiel-Ambagtsheer G; de Bruijn EA; Eggermont AM; ten Hagen TL
    Anticancer Drugs; 2006 Sep; 17(8):949-59. PubMed ID: 16940805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased local cytostatic drug exposure by isolated hepatic perfusion: a phase I clinical and pharmacologic evaluation of treatment with high dose melphalan in patients with colorectal cancer confined to the liver.
    Vahrmeijer AL; van Dierendonck JH; Keizer HJ; Beijnen JH; Tollenaar RA; Pijl ME; Marinelli A; Kuppen PJ; van Bockel JH; Mulder GJ; van de Velde CJ
    Br J Cancer; 2000 May; 82(9):1539-46. PubMed ID: 10789721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperthermic isolated limb perfusion with tumor necrosis factor alone for melanoma.
    Posner MC; Lienard D; Lejeune FJ; Rosenfelder D; Kirkwood J
    Cancer J Sci Am; 1995; 1(4):274-80. PubMed ID: 9166488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isolated hepatic perfusion for liver metastases of malignant melanoma.
    Rizell M; Mattson J; Cahlin C; Hafström L; Lindner P; Olausson M
    Melanoma Res; 2008 Apr; 18(2):120-6. PubMed ID: 18337648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I study of hyperthermic isolated hepatic perfusion with oxaliplatin in the treatment of unresectable liver metastases from colorectal cancer.
    Zeh HJ; Brown CK; Holtzman MP; Egorin MJ; Holleran JL; Potter DM; Bartlett DL
    Ann Surg Oncol; 2009 Feb; 16(2):385-94. PubMed ID: 19034580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.